Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

被引：0

作者：

Leif Bjermer

Job F. M. van Boven

Madlaina Costa-Scharplatz

Dorothy L. Keininger

Florian S. Gutzwiller

Karin Lisspers

Ronan Mahon

Petter Olsson

Nicolas Roche

机构：

[1] Skane University Hospital,Department of Respiratory medicine & Allergology

[2] Lund University,Department of General Practice

[3] Groningen Research Institute for Asthma and COPD (GRIAC),Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy

[4] University Medical Center Groningen,Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine

[5] University of Groningen,Respiratory and Intensive Care Medicine

[6] University of Groningen,undefined

[7] Novartis Sverige AB,undefined

[8] Novartis Pharma AG,undefined

[9] Uppsala University,undefined

[10] Novartis Ireland Limited,undefined

[11] Cochin Hospital (AP-HP) and University Paris Descartes,undefined

来源：

Respiratory Research | / 18卷

关键词：

Chronic obstructive pulmonary disease; Indacaterol/glycopyrronium; Cost-effective; Exacerbation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 42 条